Hypertension treatment guidelines, which have been formulated by the learned and the wise have long recommended the thiazide diuretics and betablockers as first-line drugs for the treatment of hypertension. They base this on the general 'understanding' that these agents have been around for a while and they are 'well established' to reduce heart attacks and strokes. As a pragmatic definition of hypertension is that level of blood pressure where treatment gives more benefit than harm, the use of drugs with a good track record is sound clinical practice. Is this 'understanding' that the thiazides and beta-blockers are good first-line drugs the wholehearted truth?
In most of the early trials, patients with mild to moderate hypertension were randomised to therapy with a beta-blocker or a thiazide diuretic. For example, the Medical Research Council trial (MRC, using propranolol), the International Prospective Primary Prevention Study in Hypertension (IPPPSH, using exprenolol), and the Heart Attack Primary Prevention in Hypertension trial (HAPPHY, using atenolol, propranolol and metoprolol), almost uniformly showed no significant cardioprotective effect of beta-blockers. [1] [2] [3] [4] Furthermore, a second large MRC trial of 4396 elderly hypertensives (mean age 70) found that randomisation to beta-blockers resulted in a worse outcome compared to treatment with diuretics, with a non-statistically significant trend toward fewer strokes, and no improvement in coronary disease or cardiovascular mortality. 5 By contrast, the incidence of stroke, coronary disease, and cardiovascular mortality was reduced by diuretics when compared to placebo (relative risk 0.6 to 0.7).
A recent meta-analysis by Psaty et al 6 on 48 220 patients from long term, controlled clinical trials reported that beta-blocker therapy was effective in preventing stroke and congestive heart failure, with a relative risk reduction of 29% for stroke and 42% for congestive heart failure. Despite lowering blood pressure by an average of 5-6 mm Hg, neither betablocker therapy (nor for that matter, high dose Correspondence: Dr GYH Lip diuretic therapy) showed a significant reduction of coronary heart disease events. Total mortality reduction with beta-blockers was also not significant, and neither was cardiovascular mortality reduction. By contrast, low dose diuretic therapy resulted in a significant reduction in stroke (34%), coronary heart disease events (28%), congestive cardiac failure (42%), total mortality (10%) and cardiovascular mortality (24%), when compared to controls. 6 In a recent systematic review in the Journal of the American Medical Association by Messerli et al, 7 analysis of 10 trials involving 16 164 elderly hypertensive patients (aged у60 years) found that diuretic therapy was superior to beta-blockers in preventing cerebrovascular events (odds ratio [OR] 0.61, 95% confidence interval [CI] 0.51-0.72), fatal stroke (OR 0.67, 95% CI 0.49-0.90), coronary heart disease (OR 0.74, 95% CI 0.64 -0.85), cardiovascular mortality (OR 0.75, 95% CI 0.64 -0.87) and all-cause mortality (OR 0.86, 95% CI 0.77-0.96). By contrast, betablockers only reduced cerebrovascular events (OR 0.75, 95% CI 0.57-0.98), and was actually ineffective in preventing coronary heart disease, cardiovascular mortality and all-cause mortality. Furthermore, two-thirds of the elderly hypertensive patients assigned to diuretics were well-controlled on monotherapy, whereas less than a third of patients treated with beta-blockers were well-controlled on monotherapy. 7 With the safety and proven effectiveness of low dose diuretic therapy, there is therefore no question that this class of agents is the logical first-line drug treatment for hypertension, especially in elderly patients and in patients of Afro-Caribbean origin, where beta-blockers tend to be less effective as monotherapy in view of the low renin state in such patients. Indeed, with isolated systolic hypertension, which is predominantly seen in the elderly, beta-blockers are usually less effective and good data from recent trials such as the SHEP and SYST-EUR studies suggest that the thiazides and dihydropyridine calcium antagonists would be more sensible choices. It is reassuring that the recent American guidelines (JNC-VI) have taken this on board.
Can we say the same about the effectiveness of the beta-blockers in hypertension, with equal zest and conviction? Close examination of the evidence from the trials provides some evidence that low dose diuretics may well be better than beta-blockers or high dose diuretics in the initial treatment of hypertension. At low doses, changes in glucose and cholesterol metabolism are minor, and cardiovascular morbidity and mortality are even reduced in hypertensives with hyperlipidaemia or diabetes, when diuretics are used. This has led to recent appeals for diuretics to be used more frequently, unless specific indications exist for other medications, for example, the angiotensin-converting enzyme (ACE) inhibitors for heart failure or diabetic nephropathy. 8 In the present issue of the Journal of Human of Hypertension we published a feisty debate between Professors Gareth Beevers and Martin Kendall, 9, 10 which first started as a sparring match in a local Birmingham Hypertension Society meeting. Quoting liberally the evidence from the hypertension trials discussed above, one could argue that the first round (on points but only by a whisker) perhaps goes to Beevers. Nevertheless, a gutsy rebuttal by Kendall appeals for a careful re-appraisal of the betablockers.
It is however, difficult to fully endorse a stand made by Beevers 9 that 'beta-blockers are the most unsafe of all the antihypertensive drugs'. The contention that beta-blockers may be unsafe in heart failure in myocardial damage becomes more tenuous with the large randomised trials of patients with heart failure who are given carvedilol, bisoprolol and metoprolol with a significant morbidity and mortality advantage.
11 This is with the increasing recognition that patients with heart failure have activation of both neuroendocrine and sympathetic pathways which are both related to the severity of heart failure and prognosis. Whilst beta-blockers have more subtle side effects on exercise tolerance, sleep patterns and the capacity to concentrate, these problems mainly relate to the older, non-specific lipophilic beta-blockers (such as propranolol) and newer cardioselective agents are less likely to have such problems.
The analysis by Beevers 9 of the results of the four clinical trials of the treatment of mild hypertension, comparing thiazide diuretics and beta-blockers on the development of fatal and non-fatal stroke, coronary heart disease and/or vascular deaths could also be interpreted as actually showing little difference between both groups in terms of outcomes, although in absolute terms, there were smaller numbers of events in the thiazide diuretic arms. A counter-argument may be that these trials were not designed to demonstrate equivalence of one agent with another, as such a trial in mild hypertensives (who are at relatively lower risk) would need thousands of participants to have enough power to demonstrate sufficient end-points to show equivalence.
The recognition that beta-blocker usage following acute myocardial infarction leads to improved longterm survival 12 has nevertheless raised the question of whether a similar cardioprotective effect exists in patients with essential hypertension but without clinically evident coronary disease. In experimental animals with left ventricular hypertrophy, the incidence of sudden death after coronary occlusion is reduced by beta-blocker administration but not by other agents, such as an ACE inhibitor. 13 Nearly all the randomised controlled antihypertensive trials, have failed to show the expected falls in all causes of mortality from coronary artery disease in middleage groups. The validity of using the degree of blood pressure lowering as a surrogate for the effectiveness of antihypertensive drugs on health outcomes is therefore one argument put against the increased use of newer antihypertensive agents, such as the calcium antagonists and ACE inhibitors. Indeed recent pharmacosurveillance studies have raised questions about the safety of calcium antagonists, although the ACE inhibitors may perhaps have additional benefits in diabetic nephropathy, retinopathy and even cancer.
There are however, several studies suggesting that beta-blockers actually do reduce the incidence of coronary disease in hypertensive patients. 14, 15 For example, the Metoprolol Atherosclerosis Prevention in Hypertensives Trial (MAPHY) showed a 25% reduction in coronary events with metoprolol compared to thiazides, 14 whilst the incidence of stroke was similar. However, the MAPHY study was actually a subset of the HAPPHY cohort which used atenolol, propranolol, and metoprolol and with no benefit. 3, 4 Thus, all the beta-blockers may not be the same; a specific protective effect from metoprolol could even suggest that atenolol and propranolol have a deleterious effect on coronary disease! 16 The observation that carvediolol, a vasodilatating betablocker with antioxidant properties, has benefits in heart failure, where other agents such as atenolol do not, is further testimony to the differences between beta-blockers. 11 It has also been argued that betablockers abolish the benefits of thiazide diuretics, at least in the elderly, perhaps because of their effect in reducing cardiac output.
There have nevertheless been concerns that there may be some increase in coronary risk in hypertensive patients treated with a beta-blocker. In the hypertension trials, there were often many changes in medications in the treatment groups and often more than one-half of patients in the beta-blocker group were no longer taking the drug at the end of the study. Abrupt withdrawal of beta-blockers can be associated with an increased risk of accelerated angina, myocardial infarction, or sudden death in patients with hypertension, even where there is no previous history of coronary symptoms. 17 The possibility therefore arises that withdrawal reactions from non-compliance with taking beta-blockers may have actually reduced the outcomes with respect to preventing coronary heart disease in uncomplicated hypertensive patients, who generally represent a lower risk population group. A recent case-control study also found that beta-blocker use was associated with a relative risk of 1.7 for sudden death. 18 However, as with some case-control studies, exclusion bias could perhaps explain this aberrant finding, since it is almost certain that patients at high risk for sudden death were given beta-blockers more frequently than those without high risk. It is also possible that the effect of beta-blockers might be different in certain patient subgroups, depending on the trial scrutinised. For example, the MAPHY study suggested that coronary mortality was reduced by beta-blockers in male smokers, 14 but the opposite finding was noted in two other trials, the MRC mild hypertension and elderly trials, where smokers treated with beta-blockers actually did worse than those treated with diuretics. 1, 5 Thus, the seemingly lack of benefit of the beta-blockers in treating hypertensives may actually be artifactual, due to both errors of commission or ommission.
Assuming low dose thiazides were superior to beta-blockers in hypertensives, it is not clear why and how diuretics prevent coronary heart disease events. One argument may be that low dose diuretic trials were conducted in mainly older adults where beta-blockers tend to be less effective, whilst the high dose trials were conducted in largely middleaged adults. 7, 8 From observation studies, high dose diuretic therapy is more commonly associated with an increased risk of sudden death compared to low dose diuretics, an effect that was thought to result from the metabolic side effects of diuretic therapy (such as hypokalaemia and insulin resistance). However, the deleterious effects of thiazides appear to be dose-dependent and are probably not clinically important at low doses (12.5 to 25 mg of hydrochlorothiazide or its equivalent per day. 8 If the patient with hypertension has concomitant cardiac disease, there is little doubt that the use of beta-blockers has some advantages. The evidence in favour of beta-blockers as primary treatment for patients with coronary disease is extensive, consistent and very persuasive. This is highlighted in the rebuttal by Martin Kendall 10 in our Beevers-Kendall debate. However, the question of whether the betablockers have a specific cardioprotective effect when given to patients without clinically apparent coronary disease remains unresolved. The pharmacological differences between beta-blockers may perhaps have some bearing on their outcomes, but lipophilic beta-blockers cross the blood brain more easily and account for some of the symptoms such as lethargy and reduced exercise tolerance. Whilst it is arguably true that beta-blockers should be used for secondary prevention of coronary heart disease, evidence from large surveys such as the British ASPIRE study is that we are not using beta-blockers as much as we should do.
Should beta-blocker use in hypertension be halted or re-appraised? We would be very interested in the viewpoints of our readership. The learned and the wise should hear the views of the many and carefully reappraise the evidence before passing judgement. Pontius Pilate heard the shouts of the many, panicked and hastily passed judgement before carefully evaluating the evidence-the rest is now history. Beta-blockers may yet become the antihypertensive drug class to save mankind.
